The rationale for PD-L1/PD-1 checkpoint blockade therapies is to block the PD-L1/PD-1 interaction between tumor cells and CD8+ T cells with an antibody to allow for CD8+ T cells to overcome PD-1 inhibitory signaling and eliminate the tumor cells. This evidence concerns the gene CD8A and neoplasm.